ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

… And Ebola Research At Other Companies

by Ann M. Thayer
September 28, 2015 | APPEARED IN VOLUME 93, ISSUE 38

The U.S. Biomedical Advanced Research & Development Authority (BARDA) is providing up to $38 million over the next 23 months to support Regeneron Pharmaceuticals’ development of an Ebola virus therapy in preparation for clinical trials. The drug combines three monoclonal antibodies that bind to and neutralize the virus. Meanwhile, to support clinical studies of a new Ebola vaccine under way in the U.S. and U.K., BARDA has committed $29 million over four years to Crucell Holland, part of Janssen Pharmaceutical. The agreement can be extended for up to seven years and $69 million. Denmark’s Bavarian Nordic also makes a component of the vaccine.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment